EUCTR2005-000743-29-BE进行中（未招募）不适用
Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, second and third amendment).
Heads Study Group0 个研究点开始时间: 2009年6月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Response assessment of post-transplant lymphoproliferative disorder with 18F-FDG-PET/CT and minimal residual disease monitoring, a multicenter multinational feasibility studypost-transplant lymphoma10025320PTLDNL-OMON48552niversitair Medisch Centrum Groningen30
终止
2 期
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)Post-transplantation Lymphoproliferative DisorderNCT01458548Charite University, Berlin, Germany70
尚未招募
不适用
Minimal residual disease monitoring in PTLDCirculating tumor DNA Post-transplant lymphoproliferative disorder18F-flurodeoxyglucose positron emission tomography/computed tomography Minimal residual diseaseNL-OMON22796niversity Medical Center Groningen30
已完成
Unknown
Treatment of renal transplant recipients with low bone mineral density and vascular calcification: a prospective study of alendronate therapy.Kidney transplant recipients for secondary osteoporosis and vascular calcificationJPRN-jRCT1091220155Masanori Okamoto20
已完成
2 期
Risk Stratified Sequential Treatment for CD20-positive PTLDPosttransplant Lymphoproliferative DisorderPTLDNCT00590447Charite University, Berlin, Germany152